Orbimed Advisors reduced stake in Graybug Vision, Inc. By Investing.com

<iframe src=”//rcm-na.amazon-adsystem.com/e/cm?o=1&p=22&l=ur1&category=homegarden&banner=02NMTC702K4D0VHE1SR2&f=ifr&linkID=17e0b4ac3a719000706e772761d8ae0e&t=forexz-20&tracking_id=forexz-20″ width=”250″ height=”250″ scrolling=”no” border=”0″ marginwidth=”0″ style=”border:none;” frameborder=”0″></iframe>

© Reuters. Orbimed Advisors reduced stake in Graybug Vision, Inc.

On the 25th of March, Orbimed Advisors sold 313 thousand Graybug Vision, Inc. (GRAY) shares for $1.9 million at an average price of $6.16 per share.
Shares of Graybug Vision, Inc. are down -11.53% since the transaction.

Orbimed Advisors’s holding in Graybug Vision, Inc. decreased to about 4.2 million shares with the transaction.

Orbimed Advisors first bought Graybug Vision, Inc. stock in the third quarter of 2020.
Orbimed Advisors also owns Biogen Inc (NASDAQ:), Kinnate Biopharma Inc. (KNTE), Arcutis Biotherapeutics, Inc. (NASDAQ:) and Eledon Pharmaceuticals, Inc. (ELDN).
Graybug Vision, Inc. is its number twenty eight position by number of shares and market value among pharmaceuticals stocks.

In contrast, California State Teachers Retirement System and Citigroup (NYSE:) introduced GRAY shares to their portfolio.

Orbimed Advisors has also recently sold all their shares in ObsEva SA (NASDAQ:).
Orbimed Advisors also reduced their share in Theravance Biopharma, Inc. (NASDAQ:), Otonomy, Inc. (NASDAQ:), Kala Pharmaceuticals, Inc. (NASDAQ:), Arcutis Biotherapeutics, Inc., Oric Pharmaceuticals, Inc. (ORIC) and Prelude Therapeutics Incorporat (PRLD).
The total value of the shares sold is estimated at around $88 million.

In addition, Orbimed Advisors established new holdings in VistaGen Therapeutics, Inc. (NASDAQ:).
Orbimed Advisors also added to their share in Aeglea BioTherapeutics, Inc. (AGLE).
The total value of the shares bought is estimated at around $27 million.

Orbimed Advisors also sold all their shares in Prevail Therapeutics Inc . (NASDAQ:).
This asset alone constituted 1.8% of their pre-sale portfolio.
Orbimed Advisors also reduced their share in Fluidigm Corp (NASDAQ:), Prothena Corporation plc (PRTA), Larimar Therapeutics, Inc. (LRMR), Xenon (NASDAQ:) Pharmaceuticals Inc. (XENE), Strongbridge Biopharma plc (NASDAQ:), Harpoon Therapeutics, Inc. (NASDAQ:), Turning Point Therapeutics, Inc (NASDAQ:), Passage Bio, Inc. (PASG) and Adicet Bio, Inc. (ACET).
The total value of the shares sold is estimated at around $482 million.

In addition, Orbimed Advisors added to their share in Adverum Biotechnologies Inc (NASDAQ:), Corvus Pharmaceuticals Inc (NASDAQ:), MeiraGTx Holdings plc (MGTX), X4 Pharmaceuticals, Inc. (NASDAQ:) and Applied Therapeutics, Inc. (NASDAQ:).
The total value of the shares bought is estimated at around $33 million.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


60 − 51 =